Trials / Completed
CompletedNCT00967538
Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments
Safety and Efficacy of Etanercept in Patients With Moderate to Severe Plaque Psoriasis Who Have Shown an Unsatisfactory Response to Adalimumab or Infliximab
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- Innovaderm Research Inc. · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate safety and efficacy of etanercept in patients with psoriasis who had an unsatisfactory response to adalimumab and infliximab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | etanercept 50 mg | All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks. |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2014-07-01
- Completion
- 2014-07-01
- First posted
- 2009-08-28
- Last updated
- 2014-07-24
Locations
16 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00967538. Inclusion in this directory is not an endorsement.